FDA finalises guidance on prescription drug companion apps and software labelling
The FDA has issued final guidance clarifying how prescription drug manufacturers should address companion apps and software in product labelling and regulatory submissions.
The guidance explains regulatory expectations for software distributed alongside prescription medicines, including when app content may constitute required or promotional labelling and when companion software should be reflected in prescribing information.
It also addresses submission expectations and distinctions between device-connected applications and standalone tools such as medication reminders, symptom trackers and patient coaching software, giving pharmaceutical and digital health developers a clearer regulatory framework.
Field | Content |
Article Type | Industry Updates |
Regulatory Authority | U.S. Food and Drug Administration |
Jurisdiction | United States |
Policy Type | Final regulatory guidance |
Guidance Topic | Prescription drug companion apps and software |
Guidance Announcement Date | 20 October 2026 |
Regulatory Status | Final guidance |
Affected Sectors | Pharmaceuticals; biotechnology; digital health; healthcare software |
Affected Products | Prescription medicines distributed with companion apps or software |
Key Regulatory Area | Prescription drug labelling and software-related regulatory submissions |
Labelling Considerations | When companion software content constitutes required or promotional labelling |
Prescribing Information | Circumstances in which companion software should be addressed in official prescribing information |
Submission Considerations | Materials manufacturers should provide to the FDA regarding relevant companion software |
Device-Connected Applications | Guidance distinguishes applications connected to medical devices from other software tools |
Standalone Software Examples | Medication reminders; symptom trackers; patient coaching tools |
Legal Status | Final agency guidance; not a new product marketing authorisation |
What Happened | The FDA issued final guidance addressing regulatory expectations for prescription drug apps and companion software. |
Why It Matters | Pharmaceutical manufacturers increasingly offer digital tools alongside medicines and need clarity on labelling, promotional communications and regulatory submission expectations. |
Industry Implications | Drug developers and digital health partners may need to review companion software content and associated regulatory documentation against the final guidance. |
Potential Impact | Clearer regulatory expectations may support more consistent development and communication of digital tools associated with prescription medicines. |
Key Takeaway | The FDA has finalised guidance on prescription drug companion software, clarifying labelling and submission considerations for pharmaceutical and digital health companies. |
What to Watch | Industry implementation, updates to product labelling practices, regulatory submissions and further FDA clarification. |
Primary Source | U.S. Food and Drug Administration |
Primary Source URL | https://www.fda.gov/news-events/press-announcements/fda-issues-final-guidance-prescription-drug-apps-and-software |
Relevant Date | 20 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments